RICERCA
AUTORI
RIVISTE
Sfoglia per RIVISTA
ANNALS OF ONCOLOGY
Collezione AO Alessandria
Items : 15
1639P MACADAM (MesotheliomA ClinicAl DatA platforM): A reference database as a tool for large-scale collaborative research in Annals of Oncology
2022
AO Alessandria
Cerbone L; Cunietti G; Delfanti S; De Angelis AM; Lia M; Venturelli M; Mazzucco A; Ricci D; Grosso F;
1560O Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection in Annals of Oncology
2021
AO Alessandria
Cortellini A; Roldán E; Garcia MCC; Berardi R; Sánchez A; Martinez C; Parisi A; Jones E; Bertulli RM; Rizzo G; Guida A; Chung C; Bower MD; Betti M; Vincenzi B; Mirallas O; Biello F; Queirolo P; Gennari A; Pinato DJ;
P-22 Role of timing to laparoscopic or robotic surgery after neoadjuvant chemoradiotherapy for rectal cancer: The TiMiSNAR trial in Annals of Oncology
2021
ASL Biella
AO Alessandria
Orecchia S; Fiorentino A; De Angelis N; Solaini L; Surgo A; Contardo T; Cavaliere D; Morpurgo E; De Nisco C; Cruccu A; Pulighe F; Pernazza G; Ruffo G; Perinotti R; Alongi F; Rosati R; Boni L; Elmore U; Delpini R; Monsellato I; Cassinotti E;
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study in Annals of Oncology
2019
AO Alessandria
Pagano M; Gnoni R; Bonelli C; Zanelli F; Garassino MC; Ceresoli GL; Pasello G; Tiseo M; Soto Parra HJ; Grosso F; Zucali PA; Larocca M; Torricelli F; Ciarrocchi A; Pinto C;
STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma in Annals of Oncology
2019
AO Alessandria
Ramlau R; Grosso F; Madrzak J; Krzakowski MJ; Chella A; Crinò L; Mencoboni M; Planchard D; Hiddinga B; Van Meerbeeck JP; Cedres S; Dziadziuszko R; Aerts JG; Ceresoli GL;
Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS: A computed tomography study in 151 cancer and myeloma patients in Annals of Oncology
2019
AO Alessandria
Fusco V; Fasciolo A; Gambino A; Cabras M; Erovigni F; Bianchi C; Benzi L; De Martino I; Monaco F; Rossi M; Numico G; Carossa S;
Tumor treating fields plus chemotherapy for first-line malignant pleural mesothelioma (MPM): Radiological responses in the STELLAR trial in Annals of Oncology
2019
AO Alessandria
Grosso F; Ceresoli GL;
Safety of tumour treating fields delivery to the torso: Meta analysis from TTFields clinical trials in Annals of Oncology
2019
AO Alessandria
Grosso F; Pless M; Ceresoli GL;
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial in Annals of Oncology
2019
AO Alessandria
Metaxas Y; Frueh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark MT; Schneider M; Roveta A; Perrino MRA; Biaggi Rudolf C; Froesch PR; Schmidt S; Waibel C; Appenzeller C; Rauch D; von Moos R;
SAKK 17/16-Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, singlearm phase II trial in Annals of Oncology
2018
AO Alessandria
Metaxas Y; Xyrafas A; Mark MT; Pless M; Frueh M; Froesch PR; Schneider M; Biaggi Rudolf C; Grosso F; Von Moos R;
Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM in Annals of Oncology
2018
AO Alessandria
Pagano M; Zanelli F; Gnoni R; Bonelli C; Tiseo M; Boni L; Ceresoli GL; Zucali PA; Grosso F; Pasello G; Cappuzzo F; Pinto C;
Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study in Annals of Oncology
2018
AO Alessandria
Zanelli F; Pagano M; Bonelli C; Gnoni R; Boni L; Ceresoli GL; Larocca M; Tiseo M; Zucali P; Grosso F; Cappuzzo F; Ciarrocchi A; Torricelli F; Pinto C;
2017
AO Ordine Mauriziano
AO Alessandria
Fusco V; Cabras M; Gambino A; Bertetto O; Numico G; De Martino I; Alessio M; Marinella M; Di Maio M; Baratelli C; Bironzo P; Vignani F; Bria E; Sperti E; Marcato M; Roila F;
Osteonecrosis of jaw (ONJ) after antiresorptive treatment (bisphosphonates, denosumab) of cancer-treatment induced bone loss (CTIBL): A negligible risk? in Annals of Oncology
2017
AOU Città della Salute di Torino
AO Alessandria
Gambino A; Cabras M; Fusco V; Bertetto O; De Martino I; Alessio M; Numico G; Cagnazzo C; Arizio F; Piccinni Leopardi M; Di Costanzo A; Crotto L; Matocci R; Lucarelli A; Grassi E; Saracino V; Fugazza C; Cinefra M; Marchetti F; Taverniti C; Stabile S; Monti M; Marchesi E;
Osteonecrosis of jaw (ONJ) with and without bone exposure in patients receiving antiangiogenic agents (+/-bisphosphonates or denosumab) in Annals of Oncology
2015
AO Alessandria
Fusco V; Fasciolo A; Gaino R; Tartara D; De Martino I; Alessio M; Benzi L; Rapetti M; Cammarata R; Caravaggio E; Vincenti M; Gugliemini P;